InVitro International, Inc. (IVRO)
| Market Cap | 1.58M |
| Revenue (ttm) | 811.29K |
| Net Income (ttm) | 106.70K |
| Shares Out | 22.66M |
| EPS (ttm) | 0.00 |
| PE Ratio | 17.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,000 |
| Average Volume | 6,476 |
| Open | 0.0697 |
| Previous Close | 0.0697 |
| Day's Range | 0.0562 - 0.0697 |
| 52-Week Range | 0.0250 - 0.1300 |
| Beta | -0.68 |
| RSI | 49.72 |
| Earnings Date | Apr 1, 2025 |
About InVitro International
InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System install... [Read more]
Financial Performance
In 2024, InVitro International's revenue was $811,290, an increase of 2.35% compared to the previous year's $792,628. Earnings were $106,704, an increase of 6770.83%.
Financial StatementsNews
IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances
Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid 15.4% sales advance in Q1 of FY '25, totaling $244,143; this compares favorably...
IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization
Placentia, California--(Newsfile Corp. - January 14, 2025) - InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisiti...
InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities
Placentia, California--(Newsfile Corp. - December 4, 2024) - Today InVitro International (OTCQB: IVRO) announced FY '24 sales of $811,290, up 2.4% vs. FY '23. Net income of $106,704 soared over the pr...
InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan
Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the c...
InVitro International Progresses with Growth Strategies and Continues Profitability
Placentia, California--(Newsfile Corp. - July 31, 2024) - Today, InVitro International (OTCQB: IVRO) announced third quarter FY '24 sales of $167,850, off 16% vs the same quarter last year. Net income...
InVitro International Reports Positive First Half and Second Quarter FY '24 Results; Also Planning an OTC Markets Uplisting
Placentia, California--(Newsfile Corp. - May 2, 2024) - Today, InVitro International (OTC Pink: IVRO), announced second quarter FY '24 sales of $210,615, up 5.8% compared to $199,090 for the same peri...
InVitro International Sees Real Positives in Start to FY '24
Placentia, California--(Newsfile Corp. - February 14, 2024) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technol...
InVitro International Announces Fiscal Year End 2023 and Continues Positives
Placentia, California--(Newsfile Corp. - November 13, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technol...
IVRO Announces Fiscal Q #3 2023 Results While Continuing M&A Strategy to Make Non-Animal Testing Famous
Placentia, California--(Newsfile Corp. - August 9, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 20...
IVRO Advances Core Strategy to Make Non-Animal Testing Famous, Announces Fiscal Q2 2023 Results
Placentia, California--(Newsfile Corp. - May 11, 2023) - Today InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 2023 ...
IVRO Advances Core Strategy to Make Non-Animal Testing Famous, Announces Fiscal Q1 2023 Results
Placentia, California--(Newsfile Corp. - February 8, 2023) - Today InVitro International (OTC Pink: IVRO), the 37 year pioneer developer and marketer of animal free testing methods, announced first fi...
IVRO Continues to Help Make Non-Animal Testing Famous, Releases Fiscal 2022 Results
Placentia, California--(Newsfile Corp. - December 8, 2022) - InVitro International (OTC Pink: IVRO) today announced full year FY2022 sales results of $853,511 (-15%) and net income of $21,276 (-79%).C...
IVRO Explores Opportunity for Growth
Placentia, California--(Newsfile Corp. - November 16, 2022) - InVitro International (OTC Pink: IVRO) today announced it has signed its first Letter of Intent (LOI) to acquire a privately owned, U.S. b...
IVRO Continues to Help Make Non-Animal Testing Famous, Releases Fiscal Q3 2022 Results
Placentia, California--(Newsfile Corp. - August 10, 2022) - InVitro International (OTC Pink: IVRO) today announced year to date Fiscal Year '22, and 3rd quarter financial results. Following a 2nd fisc...
IVRO with a Mission to Help Make Non-Animal Testing Famous, Releases Fiscal Q2 2022 Results
Placentia, California--(Newsfile Corp. - April 26, 2022) - InVitro International (OTC PINK: IVRO), an established leader in advancing NON-Animal testing technologies, today announced fiscal 2022 year ...
Stock Repurchase by IVRO's Management Shows Increased Confidence in Future of Non-Animal Testing
Placentia, California--(Newsfile Corp. - March 30, 2022) - InVitro International (OTC PINK: IVRO), a 30+ year leader in providing non-animal testing methods, today announced it has completed the re-pu...